Effect of methotrexate alone or in combination with sulphasalazine on the production and circulating concentrations of cytokines and their antagonists : longitudinal evaluation in patients with rheumatoid arthritis by Barrera Rico, P. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/21893
 
 
 
Please be advised that this information was generated on 2017-12-05 and may be subject to
change.
British Journal o f  R h eu m ato logy  1995;34:747-755
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ARTHRITIS
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SUMMARY
In a recent study from our group, the combination of methotrexate and sulphasalazine (MTX +  SASP) seemed superior to MTX 
alone in the treatment of rheumatoid arthritis (RA). To assess the impact of these therapies on the cytokine cascade, the in iritro 
production and circulating concentrations of several cytokines and endogenous cytokine antagonists were measured in 30 healthy 
controls and longitudinally in a subset o f 26 patients enrolled in this study. Compared to controls, RA patients had significantly 
higher circulating concentrations of interleukin-6 (IL-6), soluble receptors for tumour necrosis factor (sTNFR), soluble receptors 
for interleukin-2 (sIL-2R) and interleukin-1 receptor antagonists (IL-1RA), and their peripheral blood mononuclear cells 
(PBMNC) showed a higher spontaneous production of interleukin-1/? (IL-1 []), tumour necrosis factor a (TNFa) and IL-1RA 
(both secreted and cell-associated) and a higher stimulated production of cell-associated TNFa, IL-1RA and (to a lesser extent) 
IL-1/?. Treatment with MTX alone {n — 12) or combined with SASP (n =  14), resulted in significant reductions of circulating 
IL-6 and sIL-2R but did not alter IL-1 /?, TNFa or IL-1RA concentrations. Decreases in circulating levels of sTNFR and in 
the in vitro production of cell-associated IL-l/J and IL-1RA after stimulation were only observed in patients treated with 
MTX + SASP. The concentrations of IL-1RA and sTNFR in the circulation exceeded moderately those of IL-1 /J and TNFa 
but this is probably insufficient to block IL-1 and TNFa activity. In conclusion, therapy with MTX alone or with SASP modulates 
IL-6 and sIL-2R concentrations in RA. Decreased production of IL-1/3 and IL-1RA and circulating sTNFR levels were only 
observed during therapy with MTX +  SASP. Whether this relates to the better clinical effect observed with the combination 
therapy remains to be investigated. Circulating levels of IL-6, sIL-2R and sTNFR seem useful markers of disease activity in 
RA.
K e y  w o r d s : Cytokines, Methotrexate, Sulphasalazine, Combination therapy.
T h e  involvement of cytokine netw orks in the pathogen­
esis o f  rheumatoid arthritis (R A ) is proved beyond  
discussion [1,2]. Proinflammatory cytokines such  
as interleukin-1 (IL-1) and tum our necrosis factor a 
(TN Fa) [3, 4] are present in the rheumatoid synovial 
membrane and implicated in cell proliferation, syn­
thesis o f  prostaglandins, m etalloproteinases and inter­
leukin-6 (IL-6) [5], proteoglycan breakdown and bone  
resorption [1]. Intra-articular injection o f  IL-1 [6] and  
T N F  [7] result in joint inflam m ation and blocking IL-1 
and T N F ameliorates several animal m odels  o f  arthritis 
[8, 9]. IL-6, the major inducer o f  acute-phase response  
[10], is also present in R A  synovial tissue [2] and  
may amplify the inflammatory process by its action on  
B- and T-cells [1]. However, in contrast to IL-1 and  
TNF, IL-6 does not enhance prostaglandins or col-  
lagenase production and m ay counteract inflammation  
by enhancing the synthesis o f  tissue inhibitor o f  m etal- 
loproteinase-1 [11] and reducing IL-1 and T N F  pro-
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H
duction [12]. The role o f these cytokines in human 
arthritis is supported by preliminary studies showing 
improvement during IL-1 [13], T N F  [14], and IL-6 [15] 
blockade in RA patients.
The activity o f cytokines in biological fluids is subject 
to modulation by natural inhibitors and soluble 
cytokine receptors. The IL-1 receptor antagonist (IL- 
1RA), a competitive inhibitor o f  IL-1 which binds 
to the IL-1 receptors without inducing a biological 
response [16] is present in the rheumatoid synovial 
membrane [17]. High concentrations o f  soluble recep­
tors for IL-2 (sIL-2R) [18-20] and TNI  
[19, 21] have been detected in plasma and synovial fluid 
of RA patients. The sIL-2R, a soluble form o f  the 
a chain IL-2 receptor, is a marker of lymphocyte 
activation in vivo [2 2 ] and may be useful to monitor 
disease activity in RA [18]. The two types o f  sTN FR  
(p55 and p75) are shed from the cellular membrane 
and bind to T N F in solution acting as endogenous 
T N F antagonists [23].
Methotrexate (MTX) and sulphasalazine (SASP) are 
currently used anti-rheumatic drugs. Although their 
mechanism o f action remains unclear, several reports 
suggest that these drugs may differ in their efleets on 
circulating cytokines and cytokine production. In vitro  
studies with MTX have shown inhibitory effects on
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IL-1 [24] and IL-6 but not T N F bioactivity [25] while 
SASP has been reported to decrease IL-1 [26,27] and 
T N F  [27] production and to inhibit the binding of  
T N F a to its receptor [28]. Furthermore in RA patients, 
decreases in synovial levels o f  IL-1 /? [29], in the pro­
duction o f  IL-1 by peripheral blood mononuclear cells 
(PB M N C ) [30, 31] and in circulating concentrations o f  
IL-6, p55 sTNFR [19] and sIL-2R [19,20] have been 
reported during MTX, whereas treatment with SASP 
has been associated with reductions in IL-la, IL-1/? and 
T N F a [32], but not in sIL-2R [33] or IL-6 [32] concen­
trations, though the latter was not corroborated in
study [34].
To date o f  combination therapy with
M TX and SASP on cytokines has not been assessed.
'e, after a recent study in our centre showed 
that the combination o f M TX and SASP was superior 
to M TX alone in the treatment o f  active RA [35], we 
analysed the effects o f  these therapies on circulating
And on the in vitro  production o f several 
cytokines and their endogenous antagonists.
PATIENTS
Twenty-six patients with active RA enrolled in a 
24-week, randomized, open trial o f  MTX vs MTX in 
combination with SASP [35] and 30 healthy controls
(laboratory staff) were studied. Cytokine concen­
trations were assessed at baseline and after 4, 8 and 24
Cytokine production by PB M N C .
The production o f IL-1/?, TN Fa and IL-1RA was
sT N FR  production was not measured since 
PBM NC do not seem to release these receptors either 
spontaneously or after LPS stimulation [31]. PBM NC  
were isolated from heparinized blood by Percoll
(Pharmacia, Upsala, Sweden) centrifugation
(S 1.075g/ml) at 4°C and washed twice in saline.
PBM NC were suspended at a concentration o f 5 x 106 
cells/ml in RPM I complete medium [RPMI 1640 
medium with 20 niM HEPES (Flow, UK) supplemented 
with 2mM L-glutamine (Gibco, New York, USA), 
1 niM pyruvic acid (Sigma, St Louis, MO, USA), 
50 /ig/ml gentamicin and 5% heat-inactivated pooled 
human serum]. Aliquots o f  100 ¿¿1 (5 x 10s cells) were
*■ Jk *
added to 96-well round-bottomed microtitre plates 
(Greiner, Feirickenhausen, Germany). An equal vol­
ume o f RPMI complete medium with or without 
lipopolisaccharide (LPS) (50 ng/ml final concentration) 
was added. The plates were incubated at 37"C in a 
humidified, 5% C 0 2 atmosphere for 24 h. Thereafter, 
the supernatants containing secreted cytokines, were 
centrifuged for 5 min at 13 000#. The remaining cell 
fractions were resuspended in 200 ¿¿1 RPMI complete 
medium/well and exposed to three freeze-thaw cycles 
to lyse the cells and obtain material to measure cell- 
associated cytokines. The samples were stored at 
80°C. The RPM I culture medium, Percoll and saline 
used in this study were sterile and pyrogen-free.
weeks. Fourteen additional patients enrolled in the 
original clinical study [35] were excluded from cytokine 
measurements since they were controlled in another 
centre. Active RA was defined as a disease activity
(D A S) > 3 .  The DAS is a validated score 
composed of the Ritchie Articular Index, number o f
erythrocyte sedimentation rate (ESR) 
and patient well-being on a visual analogue scale [36]. 
Twelve patients were allocated to therapy with MTX  
alone (7.5 mg weekly in a single dose) and 14 patients
ition MTX +  SASP (2000 mg daily in 
two doses). If no clinical improvement was observed
after 1 the MTX was increas to
15 mg weekly. Non-steroidal anti-inflammatory drugs 
(N SA ID s) were kept at a stable dose and no cortico-
a t or
during the study.
M ETHODS
Circulating cytokine concentrations
Blood samples used to assess circulating cytokines 
(IL-1/?, T N F a, IL-1 RA) and soluble receptors (sIL-2R, 
sT N F R ) were drawn in Vacutainer tubes (Becton & 
Dickinson, Rutherford, NJ, USA), containing 48 jul 
E D T A -K .1 and 250 /til aprotinin (10 000 kallikrein inac­
tivating units/ml, Bayer, Mijdrecht, The Netherlands). 
IL-6 was measured in serum from a Vacutainer tube 
without additives. Samples were centrifuged 10 min at 
2 2 5 0 #  and 5 min at 15 0 0 0 #  to remove the platelets
£ frozen at C
Cytokine assays  
IL-1/?, T N F a [31] and IL-1RA [37] were assessed by 
radioimmunoassays (RIA) with an average sensitivity 
of 40, 60 and 150pg/m l, respectively. The RIAs for 
IL-1/? and IL-1RA are specific, i.e. the coexistence o f  
IL -1 /? and IL-1RA in a given sample does not alter the 
results (unpublished results and [37]). IL-6 was 
measured by a B9 hybridoma bioassay with a sensi­
tivity of 0.3 U/ml. As previously reported, this assay is 
not influenced by treatment with MTX or SASP [38].
by 
of Dr
sT N FR  (p55 and p75) were met 
linked binding assay (ELIBA) (kind 
Gallati, Hoffmann la Roche, Basel, Switzerland) with
a o f 100pg/ml. The for TN Fa
and sTN FR  measure total concentrations (both free
and complexes o f  T N F  and sTNFR) as pre-
viously repor [31]. sIL-2R was me,'11'
an enzyme-linked immunosor (ELISA)
(Innotest hIL-2Rs, Innogenetics, Antwerp, Belgium), 
according to the manufacturer’s instructions. The aver­
age sensitivity o f  this ELISA is 390 pg/ml. To minimize 
interassay variations, all samples were measured in a
STATISTICAL ANALYSIS
Baseline variables were compared using the Student 
/-test or Wilcoxon rank sum test. Closed testing pro­
cedures [39] were used to compare ne measure-
during the study with pretreatment values.
groups 
by a
i n ne concentrations
during the 24-week follow-up were
TABLE I
Clinical and laboratory parameters at baseline (mean +  s.D.), and changes after 24 weeks of treatment (mean and 95% confidence intervals)
Baseline Changes week 24 vs baseline
Variable MTX (« = 12) MTX +  SASP (n =  14) M TX MTX + SASP P
Age (yr)
Sex (female/male)
Disease duration (yr)
Previous DMARDs (number) 
Duration SASP use (months) 
RF positive (number)
Ritchie articular index
52.2 ±  13.6
9/3 
4.9 ±  4.8 
0.75 +  1.16 
23.9 ±  14.3 
10
16.6 + 5.3
58.9 ±  10.6
17/9
4.6 ±4.6  
0.79 + 1.01 
20.1 ±  13.8 
11
18.4 ±7.1 7.4 (-1 1  to -3 .8 ) -1 5 .4 ( - 18.5 to -12.2) <0.005
DAS 5.1 + 0.6 5.3 ±  0.9 -1 .1 (-1 .8  to -0 .5 ) -2 .8 (--3.3 to -2 .4 ) <0.001
Number swollen joints 23.7 + 6.7 22.3 ±7.1 -3 .8 ( — 6.2 to —1.3) -13.5 < - 17.5 to —9.5) <0.001
Number painful joints 21.9 +  8.2 26.2 + 6.2* -10.3 (-15.1 to -5 .4 ) -22 .6 ( - 25.8 to 19.4) <0.001
VAS wellbeing (mm) 43.4 ±  14.9 60.4 ±  25.4 -9 .2 (-25.1 to 6.8) -33 .5 ( - 46.6 to -20.4) <0.05
VAS pain (mm) 49.9 +  19.0 61.0 ±  19.5 -16.9 ( — 31.9 to —1.9) -39 .2 ( - 50.4 to -2 8 ) <0.05
Morning stiffness (min) 107 ±  93 101 ±89 - 3 0 (—105 to 45) -8 8 (- -131 to -4 6 )
Grip strength right left hand (kPa) 19.1,17.8 ±  10.5/9.5 22.4/18.4 ±  19.8/10.4 6.0/6.6 (0.6 to 11.4/0 to 13.1) 14.2/17.9> (9.3 to 19.2/9.2 to 26.7) <0.05
ESR (nun) 37.5 ±  25.3 36.9 ±  18.4 -14 .2 ( - 2 2  to -6 .3 ) —22 ( -3 1  to -13.4)
Haemoglobin (mmol I) 7.2+ 1.0 7.3 ±  0.8 0.37 (0 to 0.7) 0.14 (--0.2 to 0.4)
MCV (fl) 86.8 ±  8.7 89.8 + 6.6 0.08 (-3 .1  to 3.2) 3.09 (1.5 to 4.7) <0.05
Platelets ( x 109 1) 361 + 123 300 ± 45 - 3 2 ( - 8 5  to 21) - 3 5 ( - 5 4  to -1 6 )
CRP (mg 1) 63 + 50 77 ± 67 - 4 0 ( -  60 to -  20) -5 3 ( -9 1  to -1 6 )
DAS. disease activity score; MTX. methotrexate: SASP, sulphasalazine; DMARDs, disease-modifying anti-rheumatic drugs; VAS, visual analogue scale: RF, rheumatoid factor 
ESR. erythrocyte sedimentation rate; MCV. mean corpuscular volume; CRP, C-reactive protein.
P values refer to significant differences between therapy groups.
* Except in the number of painful joints (/><0.05) no significant difference was observed at baseline.
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distribution-free test for curve analysis [40]. Spear­
m an’s rank correlation coefficient was used to elevate 
correlations between variables at study entry, and 
between changes in variables after 24 weeks. A two- 
sided P  value o f  0.05 was considered to be significant. 
The clinical trial was an open study [35], but cytokine 
measurements were performed in a modified single­
blind fashion.
RESULTS
Clinical results
N o significant differences in pretreatment character­
istics were observed between both treatment groups 
except for the number o f painful joints which was 
higher in the group treated with combination therapy 
(Table I). After 24 weeks o f  treatment, improvement 
was observed in both treatment groups. However, the 
combination therapy proved to be superior to M TX  
alone as reflected by the more pronounced changes in 
clinical variables including the Ritchie Articular Index, 
D A S, number o f  swollen and painful joints, general 
well-being, pain score, grip strength (Table I) and the 
number o f  patients where the M TX dose was increased 
after 16 weeks because o f  lack o f improvement (n — 8, 
all but one in the M TX group). Toxicities occurred 
with similar frequency in both treatment groups and 
were observed in seven patients treated with MTX  
alone (gastrointestinal n =  5, increase in transaminases 
n =  2, headache n =  1, stomatitis n =  1) and in six 
patients treated with M TX +  SASP (gastrointestinal 
n — 2, increase in transaminases n =  5). One patient in 
the combination group dropped out at week 4 because
o f the development o f  an ‘overlap syndrome’ with 
leucopenia, lung abnormalities, skin lesions and anti-ds 
D N A  antibodies. The results o f this small open study 
suggest that the combination MTX 4- SASP is clinically 
superior and not more toxic than MTX alone [35]. 
This is currently being evaluated in large double-blind 
trials comparing M TX +  SASP versus the individual 
components.
Baseline comparisons in cytokine concentrations
Compared to healthy controls, the circulating con­
centrations o f  IL-6, soluble T N F and IL-2 receptors 
and IL-1RA and the spontaneous production of 
secreted and cell-associated IL-1 /?, TNFa and IL-1RA 
by PBM NC were significantly higher in RA patients 
(Table II). The production of cell-associated cytokines 
after in vitro  stimulation was also higher in RA patients 
and this difference was significant for T N Fa and 
IL-1RA. In contrast, the concentrations o f  IL-1/? and 
T N Fa in the circulation and the secreted amount of 
IL-1/?, TN Fa and IL-1RA after PBMNC stimulation 
were similar in patients and controls (Table II). No  
differences in pretreatment levels o f  circulating cyto­
kines or cytokine production by PBM NC were 
observed between treatment groups (data not shown). 
In RA patients, circulating IL-1RA concentrations 
were higher (median 4-fold) than those o f  IL-1/? and 
the ratio sTN FR  to T N F a  was 20-30 and 40-70 for 
p55 and p75, respectively. The spontaneous production 
of IL-1RA in vitro  exceeded that of IL-1 /? by 10-20- 
fold in the secreted fraction and 3-6-fold in the 
cell-associated fraction, respectively. In contrast, the
TABLE II
Circulating cytokines and cytokine production by PBMNC in healthy controls and RA patients at baseline. Median and (25, 75 percentile)
Variable
Circulating concentrations 
IL-1 (I 
TNFa
(pg/ml)
IL-6
p55
p75
S ÏL -2R
IL-1RA
(pg/ml)
(U/ml)
( pg/ml )
(pg/ml)
(pg/ml)
(pg/ml)
Production by PBMNC:  
Secreted without stimulation
IL-I ß
TNFot
(pg/ml)
(pg/ml)
I L - 1 /}
TNFa
(pg/ml)
(pg/ml)
IL-1RA (pg/ml)
Secreted after stimulation
IL-l/f
TNFa
(pg/ml)
(pg/ml)
IL-RA (pg/ml)
Cell-associated after stimulation
IL-l/i
TNFa
(Pg/ml)
(pg/ml)
IL-1RA (pg/ml)
Controls (n = 30)
65
105
1 , 6
950
3035
1825
220
IL-IRA (pg/ml)
Cell-associated without stimulation
(ND-90) 
(85-115) 
( 1.2- 2 .2 ) 
(630-1100)
(2710.3290)
(1300-2838) 
(205285)
100 (65 165)
72.5 (ND- 150)
2880 (2420 4070)
257 (185-510)
ND ND
1690 (1250-2200)
10 650 (6970-14 100)
2535 (1930-3590)
7745 (5360-10 600)
4985 (3080-6470)
195 (120 -230)
4860 (2750- 6780)
Patients (n = 26)
77.5
92.5 
29.4
2110
4785
312
375
152.5
5305
743
72.5
4810
10 500 
3445 
8990
7690
290
7895
PBMNC, peripheral blood mononuclear cells; ND, not detectable, NS, not significant.
(7085) 
(75 105) 
(11.5 38.9) 
(1730 2700) 
(3720 7150) 
(31507200) 
(230 520)
(155 1940) 
(65 565) 
(2480 7200)
(4851840) 
(35135) 
(12706690)
(4080 15 400) 
(15705500) 
(5760 13 200)
(3520 13 200) 
( 185 390)
14 000)
P
NS
NS
<0.001
<0.001
< 0 . 0 0 1
<0.001
0.005
< 0 . 0 0 1
0.01
0.02
< 0 . 0 0 1
< 0 . 0 0 1
0.005
NS
NS
NS
NS
0.02
0.02
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entrations o f  sT N F R  in the circulation (Fig. 1C
P B M N CRA (Fig. 2A and B) after 
sd to be higher (not significant) in patients treated
with M TX +  SASP, and significant decreases during 
follow-up were only observed in this treatment group. 
The secreted amount o f  IL-1/? after PBM NC stimu­
lation decreased after 4 weeks, especially in the 
group treated with M TX alone, however, the median 
values at week 24 were not significantly different from 
baseline (Fig. 2C). Neither the circulating levels o f  
IL-1RA (Fig. IE), IL-1/?, and T N F a nor the spon­
taneous production or the secretion o f  these cytokines 
after PBM N C  stimulation (data not shown) showed
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significant changes during the study. Longitudinal 
comparison o f circulating cytokines and cytokine pro­
duction, corrected for pretreatment values, did not 
show significant differences between treatment groups.
Interrelationships between cytokines and other p a r a ­
m eters
sTNFR and sIL-2R showed positive correlations 
with the D A S, number of swollen joints, C-reactive 
protein (CRP) and IL-6 and negative correlations with 
haemoglobin concentrations (Table III). IL-6 measure-
ments also correlated with baseline CRP (/ 0.49,
P  <  0.05) and ESR (r =  0.58, P  <  0.005). The pro­
duction of IL-l/j, T N F a and IL-1RA by PBM NC  
showed significant interrelationships but no correlation 
with circulating cytokine levels and clinical or labora­
tory measurements o f disease activity (data not shown).
D ISC U SSIO N
I n the present study circulating cytokines
(IL-l/J, T N Fa, IL-6, IL-1RA), soluble receptors (sIL- 
2R and sTN FR ) and the production o f  IL-l/i, TNFa  
and IL-1RA by PBM N C were longitudinally assessed 
in patients with active RA enrolled in a randomized 
open trial o f  M TX combined with SASP vs MTX  
alone [35]. Potential different effects o f  combination 
(M TX  +  SASP) and single drug (M TX) therapy on 
the cytokine network could be relevant since: (a) 
M TX 4- SASP seemed superior and not more toxic 
than M TX alone in the clinical study [35] and (b) 
previous reports had suggested that M TX and SASP 
may differ in their modulation o f  circulating cytokines 
and cytokine production [24-33].
Several o f  the parameters studied showed important 
changes during therapy and there were some differ­
ences between both therapy groups. Significant 
decreases in the circulating sT N FR  levels and in the 
production o f cell-associated IL-l/i and IL-1RA after 
stimulation were only observed in patients treated with 
M TX -I- SASP but not in the M TX group (Figs 1 and 
2). This difference may reflect the fact that baseline 
levels o f these parameters were higher (not significant) 
in the group treated with M TX -I- SASP, and that 
decreases are more likely to occur in this case. On the
hand, it might result from an additional or 
specific effect o f  SASP on the release o f  T N F  receptors 
and on the production ofIL-1 and its antagonist. Early 
decreases in IL-6 and sIL-2R concentrations occurred 
in both therapy groups, being also more marked in the 
group with higher pretreatment levels whereas the 
levels o f  IL -l/i, T N F a and IL-1RA in the circulation 
remained unchanged.
We have previously demonstrated that MTX therapy 
does not alter T N F a but reduces IL-6 and sIL-2R 
concentrations [19] and this has been corroborated by 
other authors [20,41]. However, our findings in 
patients receiving combination therapy do not support 
the claim that SASP reduces circulating levels o f  IL-l/i 
and T N F a as reported by Danis et al. [32].
In patients with active RA, we have observed 
reductions in the secretion o f  IL-l/i by stimulated
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Pic*. 2 -  ht vitro production of coll-associated interleukin-1// (IL-1//) 
(A), cell-associated interleukin-1 receptor antagonist (B) and secreted 
IL-I// (C) after peripheral blood mononuclear cell stimulation in 
patients treated with methotrexate (MTX) alone (dotted boxes) and 
with the combination of MTX and sulphasalazine (hatched boxes). 
Cytokine concentrations on the y -axis, time in weeks on the .v-axis. 
Horizontal line shows the median. Vertical line represents the range. 
Box shows the p75 and p25 values. A* value above the v-axis range 
and *P < 0.05 (closed testing) [39],
PBM NC after the first M TX dose [31]. Similar effects 
were observed in the present study after 4 weeks of 
MTX therapy. This effect was not progressive over the 
time, and also not observed in the group treated with 
combination therapy which had lower IL-l/i secretion 
at baseline. Therefore, although MTX may decrease 
IL-l/i secretion in some patients in the short term, it is
.■s
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TABLE III
sIL-2R and several cytokines and clinical and laboratory parameters. Spearman 
js at entry and between changes vs baseline after 24 weeks
p55
Entry
T« — —  — - ■ —♦ '  ■ . wr.V.-. ’ i w  rS ••• ,-,1 . i | | . . «
24 weeks
sIL-2R
Entry
*  1 - I»w»* . ■ ------------------------------- --------1— - - - _------------
24 weeks
-•I I I« . — 1 •- *1"---*- — -''J1
Entry
p75
-1* J  — ^  . A- . -I** -----------V .k J .
24 weeks
DAS 0.61** 0.66*** 0.48* 0.45* 0.61** 0.43*
Swollen joints 0.67*** 0.64** 0.56** 0.56** 0.59** 0.44*
CRP 0.45* 0.59** 0.35 0.52*
Haemoglobin — 0.46* -0.44* -0.40* -0.47*
p75 0.81*** 0.68*** 0.67*** 0.68***
sIL-2R 0.65*** 0.63**
IL-6 0.53** 0.52*
IL-1R A 0.61** 0.63**
DAS, disease activity score; CRP, C-reactive protein. 
***P < 0.001, **ƒ> < 0.005, *P < 0.05.
unlikely that this explains the sustained therapeutic 
effect o f  this drug. Our results show that, compared to 
healthy controls, RA patients have significantly higher:
(a) levels o f  IL-6, sIL-2R, sT N F R  and
IL-IRA, (b) spontaneous production o f secreted and 
cell-associated IL-1/?, T N F a  and IL -IR A , and (c) 
stimulated production o f  cell-associated T N F a, IL- 
1 RA and IL-1/? (not significant) by P B M N C  (Table II). 
Elevated concentrations o f  IL-6 [42,43], sIL-2R  
[18-20] and sT N F R  [19, 21] have been previously re­
ported in RA. These parameters are interrelated and 
show positive correlations with som e measures o f  
disease activity (Table III). Therefore, a decrease in 
their circulating levels during therapy probably reflects 
clinical improvement. Although it is not likely that 
these parameters will supersede current disease activity 
assessments, they may have some value as 
activity markers. In contrast, the concentrations of  
IL-l/i [44, 45] and T N F a in plasma are low and similar 
in RA patients and healthy controls. The increased 
serum T N F a concentrations reported in som e studies
[19,42,46]
T N Fa in
have due to production o f
blood sample during clotting or to 
endotoxin contamination [47, 48]. Our results corrob­
orate former findings o f  an increaj 
production [49 52] and a normal IL-1 fi secretion after 
LPS stimulation [49] in RA. With regard to the pro­
duction of T N F a in RA, previous reports have yielded 
contradictory results [51,53]. The higher spontaneous 
in vitro production of cytokines in RA may well reflect 
an activation of P B M N C  in vivo.
When the ratios o f  endogenous antagonists (IL-1 RA  
and sT N FR ) to agonists (IL-1 and T N F , respectively) 
were analysed, a moderate excess o f  the antagonists 
was observed in the circulation. The spontaneous pro­
duction o f  TL-1RA by P B M N C  was also somewhat 
higher than the IL-1 fi production but this was not the
LPS stimulation. Furthermore, we have
shown that PB M N C  from patients
do not release sT N F R  either spontaneously or after 
stimulation [31]. Since 10 500- and 30 -300-fold higher 
levels o f  IL -IR A  [16, 17] and sT N F R  [54], respectively 
are required for 50% suppression o f  IL-1 and T N F  
bioactivity, the concentrations o f  antagonists measured
in this study may not be adequate to block completely 
the effects o f  IL-1 and T N F. An imbalance between 
IL-1 and IL-IR A  has already been suggested to play a 
role in the pathogenesis o f  RA [17,55] and Lyme 
arthritis [56] and this might also be the case for TNFa  
and its soluble receptors. This hypothesis, sustained by 
the promising results o f  clinical studies with IL-IRA  
[13] and anti-TNFa monoclonal antibodies [14] in RA, 
encourages further research in the field of anticytokine 
strategies.
Taken together, our results show that circulating 
concentrations o f  IL-6, sIL-2R, sT N FR  and IL-IRA, 
the spontaneous production of IL-1 /?, TNFa and IL- 
IR A  and the cell-associated production of these cytoki­
nes after PBM N C  stimulation are elevated in patients 
with active RA. In this open study, the combination
M TX +  SASP clinically superior to MTX
alone. Reductions o f  circulating IL-6 and SÏL-2R levels 
were observed in both treatment groups, whereas 
decreases in sT N F R  concentrations and the in vitro 
production o f cell-associated IL-1 [1 and IL-IRA after 
stimulation occurred only with the combination
therapy. Whether relates to the better clinical
effect in this patient group or is a specific effect of  
SASP remains to be investigated. Furthermore, 
circulating levels and production o f endogenous antag­
onists lor IL-1 and T N F  in RA may not be sufficient 
to suppress the activity o f  these pro­
cytokines.
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